Global Hepatitis B Treatment Market Is Forecasted at US$35.63 Billion in The Year 2030 At A CAGR of 29.41% Between 2021 And 2030

Global Hepatitis B Treatment Market Is Forecasted at US$35.63 Billion in The Year 2030 At A CAGR of 29.41% Between 2021 And 2030

28th July 2021- July 28th is observed each year as 'World Hepatitis Day. The disease causes inflammation of the liver, which is responsible for severe liver diseases along with liver cancer. In sync with this year's theme,' Hepatitis can't wait', research has been going on a robust scale to fast-track the efforts on finding an effective remedy on the same. The situation is grim with every person dying every 30 seconds from the Hepatitis illness. Hepatitis B is one of the most common causes of death worldwide. The younger an individual gets infected, the higher are his chances of dealing with a long-term chronic ailment.

According to the data provided by the World Health Organization (WHO), 2 billion individuals have been infected by the deadly virus at some point in their lives. Although the likelihood of the infection remains significantly lower in the West, it is alarmingly high in Asia, the Western Pacific region, and Africa. The reasons for this are it is first transmitted to the infants, wherein the infection can get transferred from mother to child during childbirth or breastfeeding. It is typically a blood born virus. Other reasons for the rapid spread of the virus can be coming in sexual contact with an infected person, sharing needles, coming in contact with the infected blood or semen. The contamination can also spread through tattooing, piercing, and also through saliva. Certain risk factors also include the excessive consumption of alcohol.

The Global Hepatitis B Market Projection-

The Global Hepatitis B Market is forecasted at US$35.63 billion in the year 2030 at a CAGR of 29.41% between 2021 and 2030. The major driving factors for the rise in the market are the growth of the pharmaceutical industry, the rise in the aging population, increase in the healthcare expenditure, and the rapid pace of urbanization. Another factor responsible for the growing demand for the Hepatitis B treatment market is the growing middle-class population and the consequent demand to improve the lifestyle.

However, the market is not devoid of the different challenges which will bring with it. Some of the major challenges include rigid competition among the key players, the lack of basic diagnostic facilities, the high cost of medical care, and legal parameters.

Among these, the Asia-Pacific market is expected to grow at a higher rate owing to the rising population suffering from Hepatitis B.

Top players in the market are focusing on important research along with research and development to expand the treatment portfolio of the Hepatitis B market. The focus of the key market players is on therapeutics along with vaccines, but the major market share lies in therapeutics. With the growing increase in Hepatitis B, the demand for the treatment of this disease is becoming more prominent. It is also growing to grow during the forecast period.

The fastest-growing regional market is the US due to the presence of highly advanced healthcare systems along with efficient infrastructure and management.

Serious Indicators Which Are Not Be Ignored-

  • The pregnant woman needs to get tested and treated for Hepatitis B treatment.
  • Newborn babies need immediate attention if detected with Hepatitis B. New-born babies also needs to be vaccinated at birth.
  • Decision-makers need to act rapidly the treating the infection of Hepatitis B through strong funding and needs to be taken as the highest priority.
  • There needs to be Universal Health coverage for Hepatitis B disease.
  • Caring for people infected with Hepatitis B should be the topmost priority.

Treatment for Hepatitis B-

Currently, there is no treatment for acute onset of Hepatitis B. However its damage can be controlled, but it also has its limitations. It depends on the age factor, the intensity of the infection, and the progression of the virus.

The Chronic Hepatitis B infection can be treated with different oral anti-viral agents wherein the treatment can slow the spread of cirrhosis, reduce the onset of liver cancer, and can make way for the long-term survival of the person. The treatment once started will continue for the rest of their lives.

Also, the World Health Organization recommends the use of antiviral prophylaxis, for the prevention of transmission from mother to child in case of the pregnant woman. More importantly, there needs to be testing done at a great momentum to detect the Hepatitis cases early and prevent the mortality rate.

The WHO Response for Handling the Hepatitis B Virus-

The 74th World Health Assembly has noted down various Global Health Sector strategies for the period ranging from 2022-2030.

Under the Sustainable Development Agenda 2030, the WHO is working on various guidelines to reduce the fast-spreading impact of the virus and create awareness of the same.

The Notable Specifications Are-

  • Formulating various campaigns and collaborating on partnerships with top players in the market.
  • Effective organization of resources of treating the virus spread.
  • Drafting evidence-based policies and long-term solutions which will reduce the chronic effects of the virus.
  • Scaling up the screening, critical care, and treatment for the patient.
  • Reducing the spread of the chronic nature of the virus.

Unfortunately, there is no 100% cure for the onset of the Hepatitis B infection. There needs to be increased awareness programs and speeding up efforts via campaigns by governments, and various prominent organizations to eliminate the severe outbreak by the year 2030.

Need Help?

Please fill form below:

Contact Us

99 WALL STREET #2124 NEW YORK, NY 10005